A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

Inclusion Criteria

• •Subject must have a histologically/cytologically confirmed diagnosis of papillary, follicular, or anaplastic thyroid cancer (any follicular cell derived thyroid cancer).
• •Subjects must have evidence of follicular cell-derived thyroid cancer progression. In patients with anatomically stable disease, PET positive lesions will also be eligible given the poor prognostic risk for PET positive thyroid cancer.
• •Subjects must not be eligible for surgical resection.
• •Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• •Subjects must have laboratory values that fall within certain ranges.
• •Subjects must be age 18 years or older.
• •Subjects must provide written informed consent prior to any study procedures being performed.
• •Females of childbearing potential must have a negative pregnancy test prior to enrollment.
• •All eligible subjects must be willing to use adequate contraception throughout the duration of the study.
• •Subjects must be willing to submit a primary tumor tissue sample for immunohistochemical analysis.
• •Subjects have the option of providing one additional test tube of blood taken at baseline, 6 months and 1 year for banking of plasma for potential future studies (no genetic testing will be conducted). The current planned analysis is for the assessment of a potential peripheral marker for rexinoid responsive cancer - leukemia inhibitory factor (LIF)